Barriers to lung cancer treatment affect median survival rates
Paul Basilio, MDLinx | February 06, 2018
Although chemotherapy with thoracic radiation has long been established as the standard-of-care for the initial management of nonmetastatic small-cell lung cancer (SCLC), a large percentage of patients in the United States do not receive these treatments, according to research from The University of Texas MD Anderson Cancer Center, Houston, TX. The findings were published in JAMA Oncology.
For patients who received both chemotherapy and radiation, median survival was 18 months. For patients who received neither chemotherapy nor radiation, median survival was only 3-4 months.
For patients who received both chemotherapy and radiation, median survival was 18 months. For patients who received neither chemotherapy nor radiation, median survival was only 3-4 months.
The study also described obstacles encountered by patients when receiving cancer treatments, such as insurance and socioeconomic status. Lack of access to these treatments can lower overall survival for these patients.
“For patients who received both chemotherapy and radiation, median survival was 18 months,” said senior author Stephen G. Chun, MD, assistant professor of Radiation Oncology. “Among the group of patients who received neither chemotherapy nor radiation, prognosis was dismal with a median survival of only 3-4 months. In order to improve access to care and address related disparities, it is critical to understand the barriers patients face when getting treated for lung cancer.”
While patients with Federal Government insurance (Medicare/Medicaid) were just as likely to receive chemotherapy as those with private insurance, they were significantly less likely to receive radiation therapy. Being uninsured was associated with a lower likelihood of both chemotherapy and radiation administration, Dr. Chun explained.
For the retrospective, population-based study, the MD Anderson team used the National Cancer Database (NCDB), a nationwide outcomes registry of the American College of Surgeons, the American Cancer Society, and the Commission on Cancer. They identified 70,247 patients diagnosed with nonmetastatic, or limited-stage, SCLC and evaluated survival and socioeconomic factors to determine obstacles to cancer treatment utilization in the United States.
The patients were 55.3% female and 44.7% male. Initial treatment was 55.5% of patients receiving chemotherapy and radiation, 20.5% chemotherapy alone, 3.5% radiation alone, 20% neither chemotherapy nor radiation, and 0.5% not reported.
Patients who received chemotherapy and radiation had a median survival of 18.2 months. Those who were administered either chemotherapy or radiation alone had a median survival of 10.5 and 8.3 months, respectively. Patients who received neither chemotherapy nor radiation therapy had a significantly worse median survival—3.7 months—compared with all other treatment groups.
Multiple socioeconomic factors were highly associated with overall survival. Treatment at a nonacademic center, lack of health insurance, and Medicare/Medicaid coverage were also associated with significantly shorter survival.
“There are targeted access programs that provide competitive reimbursement for the administration of chemotherapy, and our findings suggest that these programs have improved chemotherapy access,” Dr. Chun said. “However, these programs give no financial assistance for radiation therapy, which could in part, explain why patients with Medicare and Medicaid were less likely to receive radiation.”
One limitation of the study was the small amount of cases with insufficient data or follow-up because the NCDB limits data collected to the first course of treatment. It is impossible to know if patients eventually received standard-of-care treatment, according to Dr. Chun. In addition, while chemotherapy and radiation are reported, the NCDB does not provide information on whether they were delivered concurrently or sequentially.
“Receiving appropriate, evidence-based therapies for limited-stage SCLC is critical, and our findings underscore the need for patients to personally advocate for the standard-of-care treatment for their cancer,” said Dr. Chun.
Additional research is planned to further define population patterns, specific treatment insufficiencies, and the contributing factors to wide-ranging care delivery.
To read more about this study, click here.